Premium
Dermal xanthomatous infiltrates after brentuximab vedotin therapy in mycosis fungoides with large‐cell transformation: A novel histologic finding
Author(s) -
Buchely Natalia,
AlRohil Rami N.,
Aung Phyu P.,
Jour George,
TorresCabala Carlos,
Prieto Victor G.,
Ivan Doina
Publication year - 2018
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.13288
Subject(s) - brentuximab vedotin , mycosis fungoides , cd30 , lymphomatoid papulosis , medicine , anaplastic large cell lymphoma , large cell , pathology , lymphoma , large cell lymphoma , cancer research , oncology , cancer , adenocarcinoma
Mycosis fungoides (MF) is the most common variant of cutaneous T‐cell lymphomas. Large‐cell transformation of MF has been associated with disease progression and overall poor outcome. The expression of CD30, which defines anaplastic large cell lymphoma (ALCL) and lymphomatoid papulosis, might also occur in a subset of patients with MF, with or without large‐cell transformation. Brentuximab vedotin is an anti‐CD30 monoclonal antibody which has been proven to be a safe and effective therapeutic agent in the treatment of CD30‐positive lymphomas, such as Hodgkin lymphoma and ALCL. Recently, brentuximab vedotin has been shown to have a significant clinical activity in treatment‐refractory or advanced MF or Sezary syndrome with a wide‐range of CD30 expression levels. We report a patient with MF tumor stage with large‐cell transformation and low CD30 expression with good response to brentuximab vedotin and unusual extensive xanthomatous changes in the follow‐up biopsy.